KRAS (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "KRAS" in Italian language version.

refsWebsite

Global rank Italian rank

17doi.org

2^nd place

7^th place

17nih.gov

4^th place

9^th place

10oadoi.org

799^th place

22^nd place

3harvard.edu

18^th place

104^th place

1web.archive.org

1^st place

1fda.gov

447^th place

644^th place

1ucsf.edu

5,479^th place

low place

doi.org

dx.doi.org

Tsuchida N, Ryder T, Ohtsubo E, Nucleotide sequence of the oncogene encoding p21 transforming protein of Kirsten murine sarcoma virus, in Science, vol. 217, n. 4563, 1982, pp. 937–939, Bibcode:1982Sci...217..937T, DOI:10.1126/science.6287573, PMID 6287573.
Scolnick EM, Papageoege AG, Shih TY, Guanine nucleotide-binding activity for src protein of rat-derived murine sarcoma viruses, in Proc Natl Acad Sci USA, vol. 76, n. 5, 1979, pp. 5355–5559, DOI:10.1073/pnas.76.10.5355, PMC 413141, PMID 228228.
Kranenburg O, The KRAS oncogene: past, present, and future, in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol. 1756, n. 2, 1º novembre 2005, pp. 81–2, DOI:10.1016/j.bbcan.2005.10.001, PMID 16269215.
Welman A, Burger MM, Hagmann J, Structure and function of the C-terminal hypervariable region of K-Ras4B in plasma membrane targeting and transformation, in Oncogene, vol. 19, n. 40, 1º settembre 2000, pp. 4582–91, DOI:10.1038/sj.onc.1203818, PMID 11030147.
Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, Schmidt K, Willson JK, Markowitz S, Zhou S, Diaz LA, Velculescu VE, Lengauer C, Kinzler KW, Vogelstein B, Papadopoulos N, Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells, in Science, vol. 325, n. 5947, 1º settembre 2009, pp. 1555–9, Bibcode:2009Sci...325.1555Y, DOI:10.1126/science.1174229, PMC 2820374, PMID 19661383.
Chiosea SI, Sherer CK, Jelic T, Dacic S, KRAS mutant allele-specific imbalance in lung adenocarcinoma, in Modern Pathology, vol. 24, n. 12, dicembre 2011, pp. 1571–7, DOI:10.1038/modpathol.2011.109, PMID 21743433.
Hartman DJ, Davison JM, Foxwell TJ, Nikiforova MN, Chiosea SI, Mutant allele-specific imbalance modulates prognostic impact of KRAS mutations in colorectal adenocarcinoma and is associated with worse overall survival, in International Journal of Cancer, vol. 131, n. 8, 1º ottobre 2012, pp. 1810–7, DOI:10.1002/ijc.27461, PMID 22290300.
Krasinskas AM, Moser AJ, Saka B, Adsay NV, Chiosea SI, KRAS mutant allele-specific imbalance is associated with worse prognosis in pancreatic cancer and progression to undifferentiated carcinoma of the pancreas, in Modern Pathology, vol. 26, n. 10, 1º ottobre 2013, pp. 1346–54, DOI:10.1038/modpathol.2013.71, PMC 4128625, PMID 23599154.
Schubbert S, Zenker M, Rowe SL, Böll S, Klein C, Bollag G, van der Burgt I, Musante L, Kalscheuer V, Wehner LE, Nguyen H, West B, Zhang KY, Sistermans E, Rauch A, Niemeyer CM, Shannon K, Kratz CP, Germline KRAS mutations cause Noonan syndrome, in Nature Genetics, vol. 38, n. 3, 1º marzo 2006, pp. 331–6, DOI:10.1038/ng1748, PMID 16474405.
Niihori T, Aoki Y, Narumi Y, Neri G, Cavé H, Verloes A, Okamoto N, Hennekam RC, Gillessen-Kaesbach G, Wieczorek D, Kavamura MI, Kurosawa K, Ohashi H, Wilson L, Heron D, Bonneau D, Corona G, Kaname T, Naritomi K, Baumann C, Matsumoto N, Kato K, Kure S, Matsubara Y, Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome, in Nature Genetics, vol. 38, n. 3, 1º marzo 2006, pp. 294–6, DOI:10.1038/ng1749, PMID 16474404.
Burmer GC, Loeb LA, Mutations in the KRAS2 oncogene during progressive stages of human colon carcinoma, in Proceedings of the National Academy of Sciences of the United States of America, vol. 86, n. 7, 1º aprile 1989, pp. 2403–7, Bibcode:1989PNAS...86.2403B, DOI:10.1073/pnas.86.7.2403, PMC 286921, PMID 2648401.
Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M, Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes, in Cell, vol. 53, n. 4, 1º maggio 1988, pp. 549–54, DOI:10.1016/0092-8674(88)90571-5, PMID 2453289.
Tam IY, Chung LP, Suen WS, Wang E, Wong MC, Ho KK, Lam WK, Chiu SW, Girard L, Minna JD, Gazdar AF, Wong MP, Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features, in Clinical Cancer Research, vol. 12, n. 5, 1º marzo 2006, pp. 1647–53, DOI:10.1158/1078-0432.CCR-05-1981, PMID 16533793.
Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ, Drugging the undruggable RAS: Mission possible?, in Nature Reviews. Drug Discovery, vol. 13, n. 11, 1º novembre 2014, pp. 828–51, DOI:10.1038/nrd4389, PMC 4355017, PMID 25323927.
Ryan MB, Corcoran RB, Therapeutic strategies to target RAS-mutant cancers, in Nature Reviews. Clinical Oncology, vol. 15, n. 11, 1º novembre 2018, pp. 709–720, DOI:10.1038/s41571-018-0105-0, PMID 30275515.
Holderfield M, Efforts to Develop KRAS Inhibitors, in Cold Spring Harbor Perspectives in Medicine, vol. 8, n. 7, 1º luglio 2018, pp. a031864, DOI:10.1101/cshperspect.a031864, PMC 6027934, PMID 29101115.
Drug Turns Cancer Gene Into ‘Eat Me’ Flag for Immune System, su ucsf.edu, UCSF, 13 settembre 2022, DOI:10.1016/j.ccell.2022.07.005, PMID 36099883.

fda.gov

FDA: Medical devices: therascreen® KRAS RGQ PCR Kit – P110030

harvard.edu

adsabs.harvard.edu

Tsuchida N, Ryder T, Ohtsubo E, Nucleotide sequence of the oncogene encoding p21 transforming protein of Kirsten murine sarcoma virus, in Science, vol. 217, n. 4563, 1982, pp. 937–939, Bibcode:1982Sci...217..937T, DOI:10.1126/science.6287573, PMID 6287573.
Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, Schmidt K, Willson JK, Markowitz S, Zhou S, Diaz LA, Velculescu VE, Lengauer C, Kinzler KW, Vogelstein B, Papadopoulos N, Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells, in Science, vol. 325, n. 5947, 1º settembre 2009, pp. 1555–9, Bibcode:2009Sci...325.1555Y, DOI:10.1126/science.1174229, PMC 2820374, PMID 19661383.
Burmer GC, Loeb LA, Mutations in the KRAS2 oncogene during progressive stages of human colon carcinoma, in Proceedings of the National Academy of Sciences of the United States of America, vol. 86, n. 7, 1º aprile 1989, pp. 2403–7, Bibcode:1989PNAS...86.2403B, DOI:10.1073/pnas.86.7.2403, PMC 286921, PMID 2648401.

nih.gov

ncbi.nlm.nih.gov

Tsuchida N, Ryder T, Ohtsubo E, Nucleotide sequence of the oncogene encoding p21 transforming protein of Kirsten murine sarcoma virus, in Science, vol. 217, n. 4563, 1982, pp. 937–939, Bibcode:1982Sci...217..937T, DOI:10.1126/science.6287573, PMID 6287573.
Scolnick EM, Papageoege AG, Shih TY, Guanine nucleotide-binding activity for src protein of rat-derived murine sarcoma viruses, in Proc Natl Acad Sci USA, vol. 76, n. 5, 1979, pp. 5355–5559, DOI:10.1073/pnas.76.10.5355, PMC 413141, PMID 228228.
Kranenburg O, The KRAS oncogene: past, present, and future, in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol. 1756, n. 2, 1º novembre 2005, pp. 81–2, DOI:10.1016/j.bbcan.2005.10.001, PMID 16269215.
Welman A, Burger MM, Hagmann J, Structure and function of the C-terminal hypervariable region of K-Ras4B in plasma membrane targeting and transformation, in Oncogene, vol. 19, n. 40, 1º settembre 2000, pp. 4582–91, DOI:10.1038/sj.onc.1203818, PMID 11030147.
Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, Schmidt K, Willson JK, Markowitz S, Zhou S, Diaz LA, Velculescu VE, Lengauer C, Kinzler KW, Vogelstein B, Papadopoulos N, Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells, in Science, vol. 325, n. 5947, 1º settembre 2009, pp. 1555–9, Bibcode:2009Sci...325.1555Y, DOI:10.1126/science.1174229, PMC 2820374, PMID 19661383.
Chiosea SI, Sherer CK, Jelic T, Dacic S, KRAS mutant allele-specific imbalance in lung adenocarcinoma, in Modern Pathology, vol. 24, n. 12, dicembre 2011, pp. 1571–7, DOI:10.1038/modpathol.2011.109, PMID 21743433.
Hartman DJ, Davison JM, Foxwell TJ, Nikiforova MN, Chiosea SI, Mutant allele-specific imbalance modulates prognostic impact of KRAS mutations in colorectal adenocarcinoma and is associated with worse overall survival, in International Journal of Cancer, vol. 131, n. 8, 1º ottobre 2012, pp. 1810–7, DOI:10.1002/ijc.27461, PMID 22290300.
Krasinskas AM, Moser AJ, Saka B, Adsay NV, Chiosea SI, KRAS mutant allele-specific imbalance is associated with worse prognosis in pancreatic cancer and progression to undifferentiated carcinoma of the pancreas, in Modern Pathology, vol. 26, n. 10, 1º ottobre 2013, pp. 1346–54, DOI:10.1038/modpathol.2013.71, PMC 4128625, PMID 23599154.
Schubbert S, Zenker M, Rowe SL, Böll S, Klein C, Bollag G, van der Burgt I, Musante L, Kalscheuer V, Wehner LE, Nguyen H, West B, Zhang KY, Sistermans E, Rauch A, Niemeyer CM, Shannon K, Kratz CP, Germline KRAS mutations cause Noonan syndrome, in Nature Genetics, vol. 38, n. 3, 1º marzo 2006, pp. 331–6, DOI:10.1038/ng1748, PMID 16474405.
Niihori T, Aoki Y, Narumi Y, Neri G, Cavé H, Verloes A, Okamoto N, Hennekam RC, Gillessen-Kaesbach G, Wieczorek D, Kavamura MI, Kurosawa K, Ohashi H, Wilson L, Heron D, Bonneau D, Corona G, Kaname T, Naritomi K, Baumann C, Matsumoto N, Kato K, Kure S, Matsubara Y, Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome, in Nature Genetics, vol. 38, n. 3, 1º marzo 2006, pp. 294–6, DOI:10.1038/ng1749, PMID 16474404.
Burmer GC, Loeb LA, Mutations in the KRAS2 oncogene during progressive stages of human colon carcinoma, in Proceedings of the National Academy of Sciences of the United States of America, vol. 86, n. 7, 1º aprile 1989, pp. 2403–7, Bibcode:1989PNAS...86.2403B, DOI:10.1073/pnas.86.7.2403, PMC 286921, PMID 2648401.
Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M, Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes, in Cell, vol. 53, n. 4, 1º maggio 1988, pp. 549–54, DOI:10.1016/0092-8674(88)90571-5, PMID 2453289.
Tam IY, Chung LP, Suen WS, Wang E, Wong MC, Ho KK, Lam WK, Chiu SW, Girard L, Minna JD, Gazdar AF, Wong MP, Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features, in Clinical Cancer Research, vol. 12, n. 5, 1º marzo 2006, pp. 1647–53, DOI:10.1158/1078-0432.CCR-05-1981, PMID 16533793.
Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ, Drugging the undruggable RAS: Mission possible?, in Nature Reviews. Drug Discovery, vol. 13, n. 11, 1º novembre 2014, pp. 828–51, DOI:10.1038/nrd4389, PMC 4355017, PMID 25323927.
Ryan MB, Corcoran RB, Therapeutic strategies to target RAS-mutant cancers, in Nature Reviews. Clinical Oncology, vol. 15, n. 11, 1º novembre 2018, pp. 709–720, DOI:10.1038/s41571-018-0105-0, PMID 30275515.
Holderfield M, Efforts to Develop KRAS Inhibitors, in Cold Spring Harbor Perspectives in Medicine, vol. 8, n. 7, 1º luglio 2018, pp. a031864, DOI:10.1101/cshperspect.a031864, PMC 6027934, PMID 29101115.
Drug Turns Cancer Gene Into ‘Eat Me’ Flag for Immune System, su ucsf.edu, UCSF, 13 settembre 2022, DOI:10.1016/j.ccell.2022.07.005, PMID 36099883.

oadoi.org

Tsuchida N, Ryder T, Ohtsubo E, Nucleotide sequence of the oncogene encoding p21 transforming protein of Kirsten murine sarcoma virus, in Science, vol. 217, n. 4563, 1982, pp. 937–939, Bibcode:1982Sci...217..937T, DOI:10.1126/science.6287573, PMID 6287573.
Kranenburg O, The KRAS oncogene: past, present, and future, in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol. 1756, n. 2, 1º novembre 2005, pp. 81–2, DOI:10.1016/j.bbcan.2005.10.001, PMID 16269215.
Welman A, Burger MM, Hagmann J, Structure and function of the C-terminal hypervariable region of K-Ras4B in plasma membrane targeting and transformation, in Oncogene, vol. 19, n. 40, 1º settembre 2000, pp. 4582–91, DOI:10.1038/sj.onc.1203818, PMID 11030147.
Chiosea SI, Sherer CK, Jelic T, Dacic S, KRAS mutant allele-specific imbalance in lung adenocarcinoma, in Modern Pathology, vol. 24, n. 12, dicembre 2011, pp. 1571–7, DOI:10.1038/modpathol.2011.109, PMID 21743433.
Hartman DJ, Davison JM, Foxwell TJ, Nikiforova MN, Chiosea SI, Mutant allele-specific imbalance modulates prognostic impact of KRAS mutations in colorectal adenocarcinoma and is associated with worse overall survival, in International Journal of Cancer, vol. 131, n. 8, 1º ottobre 2012, pp. 1810–7, DOI:10.1002/ijc.27461, PMID 22290300.
Schubbert S, Zenker M, Rowe SL, Böll S, Klein C, Bollag G, van der Burgt I, Musante L, Kalscheuer V, Wehner LE, Nguyen H, West B, Zhang KY, Sistermans E, Rauch A, Niemeyer CM, Shannon K, Kratz CP, Germline KRAS mutations cause Noonan syndrome, in Nature Genetics, vol. 38, n. 3, 1º marzo 2006, pp. 331–6, DOI:10.1038/ng1748, PMID 16474405.
Niihori T, Aoki Y, Narumi Y, Neri G, Cavé H, Verloes A, Okamoto N, Hennekam RC, Gillessen-Kaesbach G, Wieczorek D, Kavamura MI, Kurosawa K, Ohashi H, Wilson L, Heron D, Bonneau D, Corona G, Kaname T, Naritomi K, Baumann C, Matsumoto N, Kato K, Kure S, Matsubara Y, Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome, in Nature Genetics, vol. 38, n. 3, 1º marzo 2006, pp. 294–6, DOI:10.1038/ng1749, PMID 16474404.
Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M, Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes, in Cell, vol. 53, n. 4, 1º maggio 1988, pp. 549–54, DOI:10.1016/0092-8674(88)90571-5, PMID 2453289.
Tam IY, Chung LP, Suen WS, Wang E, Wong MC, Ho KK, Lam WK, Chiu SW, Girard L, Minna JD, Gazdar AF, Wong MP, Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features, in Clinical Cancer Research, vol. 12, n. 5, 1º marzo 2006, pp. 1647–53, DOI:10.1158/1078-0432.CCR-05-1981, PMID 16533793.
Ryan MB, Corcoran RB, Therapeutic strategies to target RAS-mutant cancers, in Nature Reviews. Clinical Oncology, vol. 15, n. 11, 1º novembre 2018, pp. 709–720, DOI:10.1038/s41571-018-0105-0, PMID 30275515.

ucsf.edu

Drug Turns Cancer Gene Into ‘Eat Me’ Flag for Immune System, su ucsf.edu, UCSF, 13 settembre 2022, DOI:10.1016/j.ccell.2022.07.005, PMID 36099883.

web.archive.org

OncoGenetics.Org, FDA updates Vectibix and Erbitux labels with KRAS testing info, su oncogenetics.org, 1º luglio 2009. URL consultato il 19 settembre 2022 (archiviato dall'url originale il 9 novembre 2014).